Comparison of Nuclear Matrix Protein-22 and Urine Cytology in Diagnosing Bladder Cancer by Soedarso, M. A. (Mohamad) et al.
  
 
 
Research Article 
 
 
Soedarso MA, Wahyuni YY, Tjahjati MI. Comparison of nuclear matrix protein-22 and urine cytology in diagnosing bladder cancer. Indonesian Journal of 
Cancer. 2018 Dec; 12(3): 76-9. 
 
76 
 
Comparison of Nuclear Matrix Protein-22 and Urine 
Cytology in Diagnosing Bladder Cancer 
 
Mohamad Adi Soedarso1, YinYin Wahyuni2 , Maria Immaculata Tjahjati2 
 
1
Division of Urology, Department of Surgery,  Academic Medical Center Dr Kariadi General Hospital, Diponegoro 
University, Semarang, Indonesia 
2
Department of Clinical Pathology, Academic Medical Center Dr Kariadi General Hospital, Diponegoro University, 
Semarang, Indonesia 
 
 
 
A R T I C L E  I N F O 
Article history:  
Received : 01 October 2018 
Reviewed : 12 November 2018 
Accepted : 28 November 2018 
 
Keywords:  
Bladder carcinoma, NMP-
22, Urine cytology 
 
 
 
 
 
 
 
 
*Corresponding Author: 
Mohamad Adi Soedarso
 
Division of Urology, Department of 
Surgery, Academic Medical Center 
Dr Kariadi General Hospital, 
Diponegoro University, Semarang
 
Email: drsoedarso@gmail.com 
 
  
A B S T R A C T 
Background: Urine cytology (UC) is a classic marker used to detect bladder malignancy 
through urine examination microscopically at the presence of malignant transitional 
cells that are released. UC  is also used to evaluate recurrence after past treatment. A 
new method that is simpler, faster and easier is by measuring protein in urine 
produced by malignant cells, namely nuclear matrix protein-22 (NMP-22). The aim of 
this study was to compare the diagnostic value of NMP-22 and UC to histopathological 
biopsy in diagnosing bladder carcinoma and to evaluate whether the NMP-22 test 
could be used for bladder carcinoma screening and recurrence monitoring.  
 
Methods: Diagnostic tests on 24 suspected bladder malignancies were performed by 
taking urine samples for NMP22 examination and UC. Sensitivity, specificity, positive 
predictive value and negative NMP-22 and UC on histopathological biopsy were 
analyzed. 
 
Results: Positive results were obtained in 21 (87.5%) and negative in 3 (12.5%) NMP22 
examinations. The sensitivity, specificity, positive and negative predictive values of 
NMP-22 on histopathological biopsy were 95%; 67%, 95%, 67%. Sensitivity, 
specificity,positive predictive value and negative UC on histopathological biopsy were 
38.1%; 100%, 100%, 18.8%.  
 
Conclusions: NMP-22 sensitivity is higher than UC in diagnosing bladder carcinoma. 
NMP-22 can be used for bladder carcinoma screening and for recurrence monitoring. 
 
 
 
INTRODUCTION 
 
Bladder cancer is the fifth most common malignancy 
in the world, the second most common tumor of the 
urinary tract and the second leading cause of death of 
patients with malignant urinary tract (1-3).
 
The 
prevalence of bladder malignancy in Indonesia in 2008 
was 49,531 cases, and the prevalence of Indonesian 
women suffering from bladder malignancy in 2002 was 
5.8% (6).
 
Based on its superficial transitional cells, 
bladder carcinoma can be treated only with 
transurethral resection of bladder tumor (TURBT), with 
and without chemotherapy (4,5). So, early diagnosis of 
bladder cancer determines the success of therapy. 
Cystoscopy and UC are effective diagnostic methods 
for diagnosing superficial bladder carcinoma. 
Cystoscopy is a gold standard examination to identify 
bladder carcinoma, as well as a modality to diagnose 
and monitor bladder carcinoma. UC is a classic marker 
used to detect malignancy. Microscopic UC is used to 
identify the presence of malignant and abnormal cells 
found in the urine of patients with bladder cancer. UC 
examination is very specific and non-invasive as a 
complement to cystoscopy. This examination has a fairly 
good sensitivity to detect bladder cancer with a high 
degree of malignancy but has very low sensitivity for 
cancers with low malignancy. In addition, the accuracy 
of cytology diagnosis is very dependent on the level of 
expert pathology that examined it (4,7,8,9).  
Non-invasive, objective and accurate biomarkers are 
needed not only for primary detection but also for 
monitoring. NMP-22 is a test that uses a specific nuclear 
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matrix protein (NMP) to detect bladder tumors in the 
urine. Nuclear matrix protein is part of the internal 
skeletal structure of the cell nucleus which was first 
proposed by Berezney and Coffey (1974). This protein 
plays an important role in regulating DNA replication 
and cell division. One component of the matrix protein 
is nuclear mitotic apparatus (NuMA) or NMP-22. This 
protein is involved in the distribution of cell chromatin 
to derived cells during mitosis and is found in the 
nucleus matrix of all cells. NMP-22 is released from the 
nucleus of cancer cells after cell apoptosis and is 
detected in urine (2,5,7,10). In normal conditions, NMP-
22 is found at low levels (mean 2.9 ng/ml) while patients 
with bladder carcinoma are found to have 25 times 
higher level of NMP-22 (5,7,9). 
The purpose of this study was to determine the 
diagnostic ability of NMP-22 compared with UC by using 
histopathological biopsy as the standard for diagnosing 
carcinoma of the bladder and evaluating whether the 
NMP-22 test can be used for screening and monitoring 
of bladder carcinoma.  
 
METHODS 
 
The study was conducted at Academic Medical 
Center Dr.Kariadi Hospital Semarang. The study design 
was a diagnostic test using a cross sectional method 
between August 2010 - April 2011. Samples were 
patients with suspected bladder malignancy who were 
treated at Dr. Kariadi Hospital Semarang.  
Urine cytology was performed examination using 
Shandon Cytospin, a tool used to deposit cells in glass 
objects using centrifugal force so that it is expected to 
get a representative smear preparation. 
 
Urine Sampling Method 
Morning urine specimens, central emission were 
collected and divided into 2 aliquots for urine cytology 
examination and NMP-22. The NMP-22 test is carried 
out according to the procedure contained in the NMP-
22 BladderCheck test kit (Matritech, inc). Examination 
uses the principle of immunochromatography, with 
monoclonal antibodies. Four drops of urine were 
inserted into the well and the results were read after 30 
minutes. Urine cytology examination was carried out in 
the Anatomical Pathology Department, evaluated by 
qualified pathologist. The results were classified as 
malignancy, suspected malignancy, no malignant cells, 
non-specific and normal inflammatory processes. No 
malignant cells, non-specific and normal inflammatory 
processes were considered negative. 
Patients underwent cystoscopy by qualified 
urologist, and if a suspicious tumor or lesion is seen, 
patients will be biopsied. The results of biopsy with 
cystoscopy were considered as the gold standard to 
determine the true positive. 
 
Statistics 
Data was processed using SPSS 17.0 for Windows. 
Data was processed using descriptive inferential 
(distribution, frequency, mean, standard deviation). 
Diagnostic test was done using 2×2 table then 
sensitivity, specificity, positive predictive value and 
negative predictive value were calculated. 
 
RESULTS 
 
The total count of the samples was 24. It consisted 
of 5 (20.8%) women and 19 (79.2%) men. The average 
age of the study subjects was 60.92 ± 12.90 and the 
mostly were at the age of 64 years old (65.2%). Of the 
24 urine samples examined by NMP-22, 21 (87.5%) were 
positive and the remaining 3 (12.5%) were negative. 
UC examination results were 8 (33.3%) positive and 
16 (66.7%) negative. Histopathological biopsy results 
showed that 14 (58.3%) were transitional cell 
carcinomas with various levels, 3 (12.5%) were 
urothelial carcinoma, 3 (12.5%) were adeno-carcinoma, 
squamous cell carcinoma, urothelial carcinoma 
papillary, non-specific inflammation and prostate 
hyperplasia amounting to 1 (4.17%), respectively. The 
total number of bladder carcinomas was 22 (91.7%) and 
non bladder carcinoma was 2 (8.3%). (Table 1) 
 
Table 1. Subjects characteristics 
Parameter (n=24) 
Subject 
Men 19 (79.2%) 
Women 5 (20.8%) 
Age (average ± SD) 60.92 ± 12.90 
NMP-22  
Positive (+) 21 (87.5%) 
Negative (-) 3 (12.5%) 
Urine cytology 
Positive (+) 8 (33.3%) 
Negative (-) 16 (66.7%) 
Biopsy results 
(histopathology) 
Carcinoma 22 (91.7%) 
Non 
Carcinoma 
2 (8.3%) 
 
Table 2. Comparison between NMP-22 examination results 
and histopathological biopsy 
 
 
Biopsy result (histopathology) 
Total 
+ - 
NMP-22 
Test 
+ 20 1 21 
- 1 2 3 
Total 21 3 24 
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This study showed that NMP-22 gave more positive 
results (87.5%) compared to UC (33.3%). This is in 
accordance with research conducted by Craig Zippe, et 
al who obtained 100% results for NMP-22 in detecting 
bladder cancer while UC was only 55.5% (11). (Table 2 
and Table 3) 
 
Table 3. Comparison between the results of urinary cytology 
examination with histopathological biopsy 
 
 
Biopsy result 
(histopathology) Total 
+ - 
Urine 
Cytology 
 
+ 8 0 8 
- 13 3 16 
Total 21 3 24 
 
The sensitivity and specificity of NMP-22 were 95% 
and 67%. The same results were obtained for positive 
predictive values and negative predictive values of 95% 
and 67%. UC sensitivity was 38.1% and specificity was 
100%. The positive and negative estimates were 100% 
and 18.8%, respectively (Table 4). 
 
Table 4. Diagnostic value of NMP-22 and urine cytology 
 
Variable 
Sensitivity 
(%) 
Spesificity 
(%) 
PPV 
(%) 
NPV 
(%) 
NMP22 95 67 95 67 
Urine 
Cytology 
38,1 100 100 18,7 
*PPV: positive predictive value; NPV: negative predictive value 
 
DISCUSSION 
 
Several studies have shown varying sensitivity and 
specificity of NMP-22. The average sensitivity of NMP-
22 was 66% (range 47% - 89%) and specificity 75% 
(range 60% -84%). Sensitivity increases according to 
increasing tumor stage and grade. Reported UC 
sensitivity on average was 10% - 40%. Other literature 
mentions that the sensitivity ranges between 20% - 53% 
with an average of 34%, and specificity of 83% - 99.7% 
with an average of 99% (2,12). 
This study only differentiated bladder carcinoma and 
non bladder carcinoma, so that NMP-22 sensitivity was 
higher than its specificity. Another factor is due to 
inadequate number of samples. The low sensitivity of 
UC can be caused by several things such as making poor 
preparations, poor staining, difficulty in detecting 
tumors with low gradations due to their similarity to 
inflammation, as well as the factors of expertise of the 
pathologist. 
In this study one sample gave false positive result. 
False positives on NMP-22 results can occur in situations 
of acute inflammation of the urinary tract including 
cystitis, prostatitis (43.8%), kidney stones or blisters 
(83.3%),  other genitourinary cancers such as prostate 
and kidney (20.7%), even with false-positive ileus 
reaching 100% (10,13). This is due to the fact that there 
is a process that requires rapid epithelial cell turnover. 
In this study false positive results were probably caused 
by inflammation. Ponsky, et al. stated that exclusion of 
the above can increase the specificity and positive 
predictive value of the NMP-22 test while the sensitivity 
remains high. 
It seems that NMP-22 test was easier to be accepted 
by patients. The examination time is relatively short (30 
minutes) and can be interpreted easily so that the 
patient management becomes faster. The test was also 
suitable for low-grade tumors which are difficult to be 
detected by UC. 
 
CONCLUSIONS 
 
NMP22 sensitivity was better than UC (95% vs 
38.1%) in diagnosing bladder malignancy. NMP-22 can 
be used to screen bladder malignancy, especially in 
patients with high risk factors and also to monitor 
recurrence of diseases.  
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